TVI Ovary 1
Alternative Names: TVI-Ovary-1Latest Information Update: 28 Dec 2022
At a glance
- Originator TVAX Biomedical
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Ovarian cancer
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (IV, Infusion)
- 14 Dec 2020 Preclinical trial is still ongoing in USA for Ovarian cancer (TVAX Biomedical website, December 2020)
- 14 Dec 2020 TVI ovary 1 is available for licensing as of 07 Jan 2013 (http://www.tvaxbiomedical.com/platform.shtml)